Pharmaniaga: 2013 Earnings

Pharmaniaga, a leading Malaysian healthcare company is driven by its core businesses namely, generic pharmaceuticals manufacturing and R & D, warehousing and distribution of pharmaceutical and medical products, sales & marketing as well as hospital projects.

Pharmaniaga has also created a niche in healthcare IT solutions which forms the backbone of its operations

Pharmaniaga Bhd's pre-tax profit for the financial year ended December 31, 2013 fell to RM93 million from RM103.31 million in the 2012 financial year ended December 31, 2012. Revenue rose to RM1.95 billion from RM1.81 billion.

For the fourth quarter, the pharmaceutical company's pre-tax profit rose to RM33.01 million from RM4.25 million in the same period in 2012, while revenue increased to RM567.86 million from RM482.40 million.

Pharmaniaga said the higher revenue for the current financial year was attributable to stronger contributions from its non-concession business with new tenders awarded during the year as well as an organic growth for its concession business.
On prospects, Pharmaniaga said its Logistics and Distribution Division is expected to contribute positively to the group's revenue, riding on strong demand for its concession products during the year.

"Similarly, the manufacturing division anticipates healthy growth despite the recent rise in operating costs such as for fuel and electricity, as this will be mitigated by prudent cost management," it said.

In line with its efforts to expand within emerging markets, the group intends to engage more overseas distributors and business partners as well as expand its overseas market footprint through acquisitions, it said.

"With our recently acquired new manufacturing plant in Indonesia, it is anticipated that the group's strategic manufacturing plans will contribute positively to the group's long-term revenue," it added.

Pharmaniaga said it will continue to transfer best practices from its domestic operations to accelerate business growth in its overseas operations.

"In the meantime, we will continue to devote effort to research and development of new products," it said.
Bernama: 24-02-2014.


Post a Comment